Frontiers in Immunology
Cure8 research brief
Why This Matters
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring easier and less invasive.
Who Should Pay Attention
Clinicians managing IBD, researchers studying biomarkers and noninvasive monitoring, and adult patients interested in less invasive disease activity assessment.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study suggests routinely available blood tests (CRP, ESR, platelets, albumin) plus TNF-α were associated with endoscopic inflammation and mucosal healing status. The combined multi-marker approach produced higher diagnostic accuracy in this retrospective dataset, but this is an observational single-center analysis of patients from 2022–2024.
Practical takeaways: These results add to evidence that blood biomarkers correlate with endoscopic activity, but they do not replace endoscopy for assessment of mucosal healing. Larger, prospective validation would be needed before changing clinical practice.
Keep In Mind
This is a retrospective study using institutional data; findings show association but not causation. TNF-α measurement is not universally standardized in routine care. The article is an abstract-level/full-text report from Frontiers in Immunology and appears to be a single-center study requiring external validation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Immunology
PublisherFrontiers Media SA
AuthorsLu Zhou, Jinfu Dong, Yifan Chen +5 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 20, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Current and novel biomarkers for predicting and assessing therapeutic response in inflammatory bowel disease: a systematic review.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Urinary Organic Acid Profiling by GC-MS Reveals Distinct Metabolic Signatures for Non-Invasive Diagnosis and Disease Activity Monitoring of Inflammatory Bowel Disease
Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...